# An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese

> **NCT05245994** · PHASE2 · UNKNOWN · sponsor: **Li Zhang, MD** · enrollment: 60 (estimated)

## Conditions studied

- Lung Cancer
- Small Cell Lung Cancer
- Durvalumab

## Interventions

- **DRUG:** Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib

## Key facts

- **NCT ID:** NCT05245994
- **Lead sponsor:** Li Zhang, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-21
- **Primary completion:** 2023-05
- **Final completion:** 2023-11
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05245994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05245994, "An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05245994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*